WO2004041164A3 - Kinase inhibitors - Google Patents

Kinase inhibitors Download PDF

Info

Publication number
WO2004041164A3
WO2004041164A3 PCT/US2003/034100 US0334100W WO2004041164A3 WO 2004041164 A3 WO2004041164 A3 WO 2004041164A3 US 0334100 W US0334100 W US 0334100W WO 2004041164 A3 WO2004041164 A3 WO 2004041164A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
kinase inhibitors
kinase
angiogenesis
atherosclerosis
Prior art date
Application number
PCT/US2003/034100
Other languages
French (fr)
Other versions
WO2004041164A2 (en
Inventor
George D Hartman
Jacob M Hoffman
Anthony M Smith
Thomas J Tucker
Original Assignee
Merck & Co Inc
George D Hartman
Jacob M Hoffman
Anthony M Smith
Thomas J Tucker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, George D Hartman, Jacob M Hoffman, Anthony M Smith, Thomas J Tucker filed Critical Merck & Co Inc
Priority to AU2003285007A priority Critical patent/AU2003285007A1/en
Priority to CA002503715A priority patent/CA2503715A1/en
Priority to JP2004550143A priority patent/JP2006507302A/en
Priority to EP03779322A priority patent/EP1558609A4/en
Publication of WO2004041164A2 publication Critical patent/WO2004041164A2/en
Publication of WO2004041164A3 publication Critical patent/WO2004041164A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention relates to compounds which inhibit, regulate and/or modulate kinase signal transduction, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, retinal ischemia, macular edema, diabetic retinopathy, inflammatory diseases, and the like in mammals.
PCT/US2003/034100 2002-10-30 2003-10-24 Kinase inhibitors WO2004041164A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003285007A AU2003285007A1 (en) 2002-10-30 2003-10-24 Kinase inhibitors
CA002503715A CA2503715A1 (en) 2002-10-30 2003-10-24 Kinase inhibitors
JP2004550143A JP2006507302A (en) 2002-10-30 2003-10-24 Kinase inhibitor
EP03779322A EP1558609A4 (en) 2002-10-30 2003-10-24 Kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42231302P 2002-10-30 2002-10-30
US60/422,313 2002-10-30

Publications (2)

Publication Number Publication Date
WO2004041164A2 WO2004041164A2 (en) 2004-05-21
WO2004041164A3 true WO2004041164A3 (en) 2004-10-07

Family

ID=32312490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034100 WO2004041164A2 (en) 2002-10-30 2003-10-24 Kinase inhibitors

Country Status (5)

Country Link
EP (1) EP1558609A4 (en)
JP (1) JP2006507302A (en)
AU (1) AU2003285007A1 (en)
CA (1) CA2503715A1 (en)
WO (1) WO2004041164A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CN111116575B (en) * 2019-12-18 2021-06-15 浙江工业大学 5-fluoro-2, 4-pyrimidinediamine compound and preparation and application thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
AR045047A1 (en) * 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
MXPA06014129A (en) * 2004-06-04 2007-03-07 Arena Pharm Inc Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto.
JP4954085B2 (en) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド Ibudilast for the treatment of neuropathic pain and its associated symptoms
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
PT1874313E (en) 2005-04-29 2010-10-21 Ferring Int Ct Sa Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain
US8034954B2 (en) * 2005-12-22 2011-10-11 Icagen, Inc. Calcium channel antagonists
ES2378704T3 (en) * 2006-01-27 2012-04-17 Array Biopharma, Inc. Glucokinase activators
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP4782239B2 (en) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク Sulfonylamide derivatives for the treatment of abnormal cell proliferation
US8507498B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
EP2209778B1 (en) 2007-09-21 2012-08-29 Array Biopharma, Inc. Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
WO2010059384A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
CN103221410B (en) 2010-09-22 2017-09-15 艾尼纳制药公司 GPR119 receptor modulators and the treatment to relative obstacle
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
WO2012149528A1 (en) * 2011-04-29 2012-11-01 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Crystalline free-plate habit of l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid
TWI620748B (en) * 2016-02-05 2018-04-11 National Health Research Institutes Aminothiazole compounds and use thereof
JP2020507611A (en) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Compounds and methods for the treatment of primary biliary cholangitis
TWI667236B (en) * 2017-06-13 2019-08-01 財團法人國家衛生研究院 Aminothiazole compounds as protein kinase inhibitors
CN111388656B (en) * 2020-04-17 2021-01-15 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Application of Kallistatin protein in preparation of medicine for preventing and treating OHSS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062778A1 (en) * 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
WO2002045652A2 (en) * 2000-12-04 2002-06-13 Merck & Co., Inc. Tyrosine kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231139B2 (en) * 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062778A1 (en) * 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
WO2002045652A2 (en) * 2000-12-04 2002-06-13 Merck & Co., Inc. Tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1558609A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CN111116575B (en) * 2019-12-18 2021-06-15 浙江工业大学 5-fluoro-2, 4-pyrimidinediamine compound and preparation and application thereof

Also Published As

Publication number Publication date
CA2503715A1 (en) 2004-05-21
WO2004041164A2 (en) 2004-05-21
EP1558609A4 (en) 2008-05-28
EP1558609A2 (en) 2005-08-03
AU2003285007A1 (en) 2004-06-07
JP2006507302A (en) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2004052315A3 (en) Tyrosine kinase inhibitors
WO2004041164A3 (en) Kinase inhibitors
WO2004052286A3 (en) Tyrosine kinase inhibitors
WO2003092595A3 (en) Tyrosine kinase inhibitors
WO2002045652A3 (en) Tyrosine kinase inhibitors
WO2001029025A3 (en) Tyrosine kinase inhibitors
WO2001028993A3 (en) Tyrosine kinase inhibitors
WO2003037252A3 (en) Tyrosine kinase inhibitors
AU3857501A (en) Tyrosine kinase inhibitors
IL148385A0 (en) Tyrosine kinase inhibitors
WO2002032861A3 (en) Orally active salts with tyrosine kinase activity
ATE316088T1 (en) TYROSINE KINASE INHIBITORS
WO2003088900A3 (en) Solid forms of salts with tyrosine kinase activity
WO2007149427A3 (en) Tyrosine kinase inhibitors
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2006078574A3 (en) Mitotic kinesin inhibitors
WO2006078575A3 (en) Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4- d] pyrimidines as inhibitors of mitotic kinesins
WO2006031348A3 (en) Mitotic kinesin inhibitors
WO2003020699A3 (en) Tyrosine kinase inhibitors
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2006078598A3 (en) Mitotic kinesin inhibitors
WO2003015717A3 (en) Tyrosine kinase inhibitors
WO2007050401A3 (en) Tyrosine kinase inhibitors
WO2005060654A3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003285007

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003779322

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2503715

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004550143

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003779322

Country of ref document: EP